Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
F. Cappuzzo
Institutions:
Istituti Fisioterapici Ospitalieri,
Instituto Nazionale Tumori Regina Elena
Observed institutions:
Istituti Fisioterapici Ospitalieri,
Ospedale di Livorno,
Istituti di Ricovero e Cura a Carattere Scientifico,
Instituto Nazionale Tumori Regina Elena
ORCID:
0000-0002-6295-6767
Observed ORCID:
0000-0002-6295-6767
OpenAlex ID:
A5033016871
Correlation between treatments and outcomes of patients with EGFR-mutated non-small-cell lung cancer that transitioned into small-cell lung cancer: an international retrospective study
2025
·
C. Catania
, S.V. Liu
, et al.
·
ESMO Open
·
31
PDF
LBA11 IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen
2022
·
S.M. Lee
, C. Schulz
, et al.
·
Annals of Oncology
·
26
PDF
PL02.12 Ivonescimab vs Placebo Plus Chemo, Phase 3 in Patients with EGFR+ NSCLC Progressed with 3rd gen EGFR-TKI Treatment: HARMONi
2025
·
J.W. Goldman
, A. Passaro
, et al.
·
Journal of Thoracic Oncology
·
25
LBA7 The Rome trial from histology to target: The road to personalize targeted therapy and immunotherapy
2024
·
A. Botticelli
, S. Scagnoli
, et al.
·
Annals of Oncology
·
25
1394TiP KRYSTAL-7: A phase III study of first-line adagrasib plus pembrolizumab versus pembrolizumab alone in patients with advanced NSCLC with KRASG12C mutation
2024
·
M.C. Garassino
, P.A. Jänne
, et al.
·
Annals of Oncology
·
15
PDF
LBA2 SKYSCRAPER-06: Efficacy and safety of tiragolumab plus atezolizumab plus chemotherapy (tira + atezo + chemo) vs pembrolizumab plus chemotherapy (pembro + chemo) in patients (pts) with advanced non-squamous non-small cell lung cancer (NSq NSCLC)
2024
·
M.A. Socinski
, D. Rodriguez Abreu
, et al.
·
Immuno-Oncology Technology
·
14
Global advances and future directions in lung cancer care: expert consensus and strategic priorities
2026
·
M.-L. Meyer
, S. Peters
, et al.
·
ESMO Open
·
13
PDF
Crizotinib: from discovery to accelerated development to front-line treatment
2017
·
F. Blackhall
, F. Cappuzzo
·
Annals of Oncology
·
12
OA08.07 Sacituzumab Govitecan + Pembrolizumab + Carboplatin in 1L Metastatic Non-Small Cell Lung Cancer: The EVOKE-02 Study
2024
·
J. Gray
, J. Neal
, et al.
·
Journal of Thoracic Oncology
·
5
PDF
70MO Genomic profiling to expand precision cancer medicine in the real world: The ROME trial
2023
·
A. Botticelli
, S. Scagnoli
, et al.
·
ESMO Open
·
4
PDF
15P Intracranial (IC) efficacy of ivonescimab (ivo) plus chemotherapy (chemo) in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutated non-small cell lung cancer (NSCLC) in the HARMONi study
2026
·
X. Le
, A. Passaro
, et al.
·
ESMO Open
·
3
PDF
P3.18.61 KRYSTAL-4: Phase 3 Study of Adagrasib Plus Pembrolizumab and Chemotherapy Intreatment-Naïve, Advanced KRAG12C-Mutated NSCLC
2025
·
J. Naidoo
, P.A. Jänne
, et al.
·
Journal of Thoracic Oncology
·
3
The role of the molecular tumor board: learnings from the ROME trial
2026
·
P. Marchetti
, G. Curigliano
, et al.
·
npj Precision Oncology
·
2
PDF
127TiP: RELATIVITY-1093: A randomized, phase III study of first-line nivolumab (NIVO) + relatlimab (RELA) high dose (HD) with platinum-doublet chemotherapy (PDCT) vs pembrolizumab (PEMBRO) + PDCT in patients with metastatic NSCLC having tumor PD-L1 expression ≥ 1% and non-squamous (NSQ) histology
2025
·
S. Peters
, N. Girard
, et al.
·
Journal of Thoracic Oncology
·
2
PDF
233P: Chemo-immunotherapy for borderline resectable and unresectable NSCLC
2025
·
F. Cappuzzo
, L. Landi
, et al.
·
Journal of Thoracic Oncology
·
2
PDF
P2.10A.06 Phase 3 TroFuse-004 Study: Sac-TMT vs Chemotherapy for Previously Treated Advanced NSCLC with EGFR/Other Genomic Alterations
2024
·
E.B. Garon
, F. Cappuzzo
, et al.
·
Journal of Thoracic Oncology
·
2
PDF
1397TiP Phase III trial of the therapeutic cancer vaccine OSE2101 versus docetaxel in patients with metastatic non-small cell lung cancer and secondary resistance to immunotherapy
2024
·
S.V. Liu
, R. Dziadziuszko
, et al.
·
Annals of Oncology
·
2
PDF
1213P Neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS vs. neoadjuvant placebo (PBO) plus CT with adjuvant PBO in resectable non-small cell lung cancer (NSCLC): patient-reported outcomes (PRO) in the RATIONALE-315 trial
2024
·
F. Cappuzzo
, C. Wang
, et al.
·
Annals of Oncology
·
2
PDF
1504TiP HARMONi: Randomized, double-blind, multi-center, phase III clinical study of ivonescimab or placebo combined with pemetrexed and carboplatin in patients with EGFR-mutant locally advanced or metastatic non-squamous NSCLC who have progression following EGFR-TKI treatment
2023
·
W. Fang
, F. Cappuzzo
, et al.
·
Annals of Oncology
·
2
PDF
246P Acasunlimab monotherapy or with pembrolizumab in CPI-treated mNSCLC: Primary phase II results
2025
·
L. Paz-Ares
, J.G. Aerts
, et al.
·
Immuno-Oncology Technology
·
1
PDF
P3.18.74 BNT324-01: A Phase 1b/2 Trial of BNT324/DB-1311 (B7H3 ADC) With BNT327 (PD-L1 x VEGF-A bsAb) in Lung Cancer (SCLC or NSCLC)
2025
·
A. Schoenfeld
, A. Spira
, et al.
·
Journal of Thoracic Oncology
·
1
109P: Enhancing enrollment to 1L NSCLC trials by allowing 1 prior cycle of standard of care (SOC): SUNRAY-01 experience
2025
·
M.J. Hochmair
, K.C. Arbour
, et al.
·
Journal of Thoracic Oncology
·
1
PDF
350P: Spatial and single-cell transcriptomics to characterize T/B cell immune structures and neighborhood stromal components associated to immunotherapy response in non-small cell lung cancer
2025
·
N. Porciello
, L. D’Ambrosio
, et al.
·
Journal of Thoracic Oncology
·
1
PDF
EP.12B.03 Cognitive Impact of Lorlatinib Administration in Advanced Non Small Cell Lung Cancer with ALK and ROS1 Fusions
2024
·
A. Tanzilli
, L. Tosetto
, et al.
·
Journal of Thoracic Oncology
·
1
PDF
P2.05-02 MAPK1/MAPK3 Mutations Enhance Immunotherapy Efficacy in Lung Squamous Cell Carcinoma (LSCC): Results of the SQUINT Trial
2023
·
F. Cappuzzo
, F. Fusco
, et al.
·
Journal of Thoracic Oncology
·
1
PDF
Show more works
View as search
Works count:
69
Citation count:
199
H-index:
8
I10-index:
8
Year
Topic
Type